Figure 1: Upregulation of CXCR4 in HCC correlated with poor patient survival.
From: EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
(a) Representative immunohistochemistry (IHC) staining with CXCR4 (scale bar, 50 μm). (b) Scatter plots for corresponding evaluated IHC score in tumour and peritumour HCC specimens (n=127). The horizontal lines in the plots represent the median and the interquartile range. The P values were calculated using Student’s t-test. (c) Western blot analysis of CXCR4, GAPDH in cytoplasmic extracts (Cyto) and CXCR4, lamin B1 in nuclear extracts (NE) in HCC specimens. Data are representative immunoblots of three independent assays. (d) Representative IHC staining with CXCR4 from TNM stage I to III of HCC specimens (scale bar, 50 μm)(left panel). Scatter plots for corresponding evaluated IHC score from TNM stage I to III of HCC specimens (right panel). Error bars represent mean±s.d. IHC scores were compared by one-way analysis of variance and Student’s t-test, *P<0.05. (e,f) Kaplan–Meier plots indicate the overall survival (e) and RFS (f) for HCC patients categorized by CXCR4 expression (n=63 for high-CXCR4 group versus n=64 for low-CXCR4 group), P value is determined by log-rank test.
